Navigation Links
A Screen of shRNAs Targeting Tumor Suppressor Genes to Identify Factors Involved in Paclitaxel Sensitivity

Diana Ji, Stacy L. Deeds, and Edward J. Weinstein

RNA interference methodologies have been utilized in small to large scale screening projects. The technology has allowed researchers to perform gene-silencing experiments in timeframes and target cells previously not possible. While siRNA screens have become fairly common, large scale screening with shRNA is still evolving. Advantages of shRNA-based experiments include long-term knockdown and viral delivery to non-transfectable cell types.

We set out to develop strategies for using lentiviral-based shRNA libraries in larger scale silencing projects (see Figure 1 for library vector map). Pilot screens using a tumor suppressor gene family set were performed to address biologically relevant questions while simultaneously developing screening strategies that could be used by a variety of researchers in the field.

A topic that has been extensively investigated is the effectiveness of chemotherapy for treating various carcinomas. A major cause of mortality in the United States, lung cancer, accounts for approximately one third of cancer-related deaths and has a low 5-year survival rate with few patients responding effectively to chemotherapy.

One potential treatment for lung carcinoma is paclitaxel. This anti-cancer agent (produced by Bristol-Meyers Oncology) functions by stabilization of microtubules so they cannot depolymerize. It effectively shifts the equilibrium in cells towards microtubule assembly, disrupting the normal operation of the microtubule network and thereby arresting the mitotic process.

Treatment with paclitaxel alone, however, is effective in only a fraction of the population. Approximately 21% to 24% of patients with non-small cell lung carcinoma (NSCLC) will respond to a regimen with this single agent. As a result, first line therapy may involve multiple chemotherapeutics, often combining paclitaxel with one, or sometimes two, additional chemotherapies, including cisplatin, carboplatin, or radiation treatment.

Since chemotherapy is toxic and stressful to a patient, there is an obvious benefit to limiting the amounts of these toxic compounds administered. If patients who are likely to positively respond to paclitaxel as a single agent could be identified prior to treatment, they may be spared the unnecessary pain associated with combination regimens. One potential way to do this is through employment of pharmacogenomics.

The first step in a potential strategy would be to categorize patients based on the molecular profile of their tumor. This can be effectively accomplished through use of microarrays (on an RNA level), array CGH (on a DNA level), or protein chips. This type of work is well established and has been thoroughly reviewed elsewhere.

After understanding the profile of a tumor, one still must determine which molecular signature is indicative of responsiveness to a drug, and which is not. We utilized an shRNA screen to help elucidate this question, specifically in the case of NSCLC and paclitaxel treatment.

Various transcripts were down-regulated using lentiviral-based shRNAs found in a panel targeting tumor suppressor genes (Sigma-Aldrich, MISSION ↓ TRC shRNA Human Tumor Suppressors, SH0531) in lung cancer cells grown under standard conditions. Transductions were performed in 96-well plates, with each well receiving cells and a single shRNA delivered by lentiviral particles. The entire tumor suppressor panel, consisting of approximately 75 gene targets each represented by 3-5 individual shRNA clones, fits onto five 96-well plates. After selection of transduced cells with puromycin, each well was split1:2 (2 sets of 5 x 96-well plates). One set of plates was mock-treated while the second set was treated with paclitaxel. Cell growth was then assessed in all wells (Figure 2). All values were normalized to a negative control (cells infected with an empty vector-containing lentivirus).

This screen allows one to identify genes involved in cell survival, and more importantly, it is designed to identify which shRNAs (and therefore which genes) will assist in making a cell more sensitive, or more resistant, to paclitaxel (Figure 2). We identified several genes that lead to increased resistance to treatment. This correlates with published examples of cases in which patients carrying mutations or deletions of tumor suppressor genes have a lower rate of response to a variety of therapies. Prominent among those genes is p53, which was found to play a role in paclitaxel resistance in our screen as well.

More intriguing is the finding that some genes, when down-regulated by these shRNAs, lead to increased sensitivity of cells to paclitaxel (Figure 3). Again, there is evidence in the literature to support this finding. BRCA1 has been found to be mutated in breast and ovarian tumors, and patients with these mutations can be more responsive to chemotherapies than patients with this gene intact. Patients with renal cell carcinoma and a mutation or truncation in the VHL tumor suppressor gene have better response rates and a longer time to tumor progression when treated with a certain molecular therapy than patients with a functioning VHL. The gene VHL was also identified in our screen.

It is important to note that these experiments are preliminary and it is difficult to conclude the role of specific genes identified and their potential relevance to actual clinical outcomes, however, the implications are promising. Our experiments imply that by examining the molecular state of a tumor and determining the levels of certain tumor suppressor genes, one might be able to determine the likelihood of response to a therapy. Patients with tumors containing high levels of some genes, such as p53, would be expected to respond less well to paclitaxel, perhaps falling into the group of 80% non-responders, while patients with low levels of other genes, such as VHL, would be expected to respond better to this drug (perhaps falling into the 20% clinical responder population).

An advantage to the use of shRNA is that it allows an investigator to rapidly validate results in multiple model systems. We are encouraged by our findings in this one non-small cell lung carcinoma line and want to attempt to validate the results in additional lines. We are similarly interested in determining whether these genes play a role only in NSCLC, or if they also affect response rates in cell lines derived from other tumor types. We can do this fairly simply with lentiviral delivery of shRNA with little, or no, additional optimization of conditions necessary. Unlike the more traditional siRNA approach, we do not need to optimize transfection or reaction conditions for each new cell line transduction is usually as simple as growing cells and adding lentivirus to the media. Also unlike siRNA, shRNA allows one to have a long-term down-regulation of a gene. This will facilitate our moving from an in vitro setting to an in vivo experiment. After confirmation of our results in mouse xenograft models, we hope to examine the clinical setting to see if patients who have been treated with paclitaxel in the past have a gene expression profile correlating with our findings. If so, these elucidated genes will have exciting possibilities, either as targets or biomarkers for paclitaxel sensitivity.

For more information on the MISSION TRC shRNA collections, visit

Figure 1
Features of the pLKO.1-Puro vector allow for transient or stable transfection of the shRNA as well as production of lentiviral particles. Unlike adenovirus or murine-based MMLV or MSCV retroviral systems, lentiviral-based particles permit efficient infection and integration of the specific shRNA construct into differentiated and non-dividing cells, overcoming low transfection and integration difficulties when using these cell lines. pLKO.1 allows for long-term knockdown and phenotypic observation and transduction of difficult or sensitive cell lines.

Figure 2. Screening Tumor Suppressor Knockdown Cells for Paclitaxel Sensitivity.
The MISSION TRC Human Tumor Suppressor Gene Family Set (Cat. No. SH0531) was used to screen for genes that could enhance cell sensitivity to the widely used cancer therapy drug, Paclitaxel. Lentiviral particles were used to transduce cells in 96-well plates and knock down the corresponding tumor suppressor gene expression. Cells were split into two samples. One sample set was treated with Paclitaxel and the second set received medium only. Results were normalized to pLKO.1-puro empty vector control virus (Cat. No. SHC001V). Outliers were observed that either conferred more resistance or sensitivity to Paclitaxel treatment. The red data point represents a positive control for increased sensitivity to Paclitaxel.

Figure 3. Multiple MISSIONTM shRNA Clones Per Target Produce the Same Phenotype.
Multiple clones for four genes conferred increased cell sensitivity to drug treatment. These genes have the potential to be prognostic markers in chemotherapeutic responses.

Similar article originally printed in Genetic Engineering News , Jan. 15, 2007.



Page: All 1 2 3 4 5 6

Related biology technology :

1. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
2. Screening of Beer-Spoilage Bacteria Using the LightCycler PCR Workflow System
3. LightCycler foodproof Beer Screening Kit
4. Perform RNAi Library Screens on Any Budget
5. Recommendations for Successful siRNA Library Screens
6. Setting up Successful siRNA Library Screens
7. Temporal Temperature Gradient Electrophoresis: A Powerful Technique to Screen Mutations
8. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
9. Screening for potential beta 2-adrenergic receptor antagonists using CypHer5E and IN Cell Analyzer 1000
10. Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000
11. A Mix-and-Read Cell-Based Assay for Hybridoma Screening Using the FMAT 8100 HTS System
Post Your Comments:
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and OpenBiome Partner ... mechanics of fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome ... undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... hydrophilic filter that does not sacrifice selectivity to achieve faster flow rates in ... extremely fine pores with significant open space to allow easy liquid flow while ...
(Date:6/30/2015)... ... June 30, 2015 , ... Noblis, Inc., ... announced in a paper published this week in the scientific journal Viruses ( ... diagnostic techniques currently used to detect the Ebola virus. Noblis worked with the ...
(Date:6/30/2015)... ... ... The maximum number of shares proposed to be purchased in the tender ... restricted stock). On June 29, 2015, the last trading day prior to the commencement ... OTCBB was $2.29 per share. , The tender offer will expire on July 28, ...
Breaking Biology Technology:uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3New Nanofiber Membrane Provides Fast, Efficient Filtration 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... research led by the U.S. Department of Energy,s Argonne ... understanding of new mechanisms, which makes it possible to ... may enable computers to more accurately write and store ... of Hamburg used a special scanning tunneling microscope equipped ...
... has been used for years to cool trapped atomsand ... thermal motion. Now, applying a different form of radiation ... of Standards and Technology (NIST) have used radio waves ... containing more than a quadrillion atoms, a cooling technique ...
... 14 Viragen, Inc. (OTC,Bulletin Board: VRAI) ... Bulletin Board: VRGE), today jointly announced,that Viragen ... Sweden, filed an application seeking protection under ... a,multi-subtype, human alpha interferon. The bankruptcy ...
Cached Biology Technology:Researchers improve ability to write and store information on electronic devices 2'Radio wave cooling' offers new twist on laser cooling 2Viragen International's Subsidiary, ViraNative AB, Files to Seek Bankruptcy Protection in Sweden 2
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
(Date:6/29/2015)... , June 24, 2015 ... of the "Latin America Biomedical Sensors Market - ... offering. The Latin America Biomedical Sensors market ... CAGR of 2.04% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... August 13, 2013, S. Korea. A collaboration between the ... Pasteur Korea (IP-K) to spur the fight against neglected ... entered into a Master Research Agreement for collaboration in ... treatments for patients suffering from neglected diseases. Under the ...
... been recently published in Geophysical Research Letters ( ... JGR-B ) and Journal of Geophysical Research-Atmospheres ( ... in Japan caused large waves in Norwegian fjords, 2. Disposal ... The Arctic is especially sensitive to black carbon emissions from ...
... switch that can either increase or decrease memory-building activity ... Its dual role means the protein is key to ... brain,s circuitry, the researchers say. A description of their ... Journal of Neuroscience ., "What,s interesting about this ...
Cached Biology News:Institut Pasteur Korea -- DNDi come together for the fight against neglected diseases 2AGU journal highlights -- Aug. 13, 2013 2AGU journal highlights -- Aug. 13, 2013 3AGU journal highlights -- Aug. 13, 2013 4AGU journal highlights -- Aug. 13, 2013 5AGU journal highlights -- Aug. 13, 2013 6AGU journal highlights -- Aug. 13, 2013 7AGU journal highlights -- Aug. 13, 2013 8Newly discovered 'switch' plays dual role in memory formation 2
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
TACS Apoptotic DNA Laddering Kits are used to assay cells and tissues for apoptosis by...
Biology Products: